Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

Read More

Ligand Reports Third Quarter 2016 Financial Results

Read More

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections

Read More

Recent Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range